Purpose of this Study
We are doing this study to find out the safest and most effective dose of the study drug (RP-3500) is when given alone or in combination with talazoparib.
Who Can Participate?
Eligibility
Adults with advanced cancer resistant to standard treatment with documented changes in certain genes.
What is Involved?
If you choose to join this study you will:
-Go through a screening period to see if you qualify for the study
-Take the study drug (RP-3500) by mouth 1 or 2 times a day according to the assigned schedule
-Provide old tumor tissue
-Have physical exams, blood and urine tests
-Have imaging scans (CT and/or MRI)
Some people will also:
-Take talazoparib by mouth once daily
-Have tumor samples taken
-Go through a screening period to see if you qualify for the study
-Take the study drug (RP-3500) by mouth 1 or 2 times a day according to the assigned schedule
-Provide old tumor tissue
-Have physical exams, blood and urine tests
-Have imaging scans (CT and/or MRI)
Some people will also:
-Take talazoparib by mouth once daily
-Have tumor samples taken
Study Details
Full Title
Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with ATR inhibitor Sensitizing Mutations (TRESR Study)
Principal Investigator
Niharika
Mettu
Protocol Number
PRO00106181
NCT ID
NCT04497116
Phase
I/II
Enrollment Status
OPEN TO ACCRUAL